Manual drainage versus Lymphassist® at 40mm Hg: Comparative plethysmographic study on upper limb lymphoedema  by Deltombe, T. et al.
L. Taillandier
Service neurologie, CHU de Nancy, hôpital central, 29, avenue du Maréchal-
de-Lattre-de-Tassigny, 54000 Nancy, France
E-mail address: inconnu@chu-nancy.fr
Keywords: Oncology; Physical medicine and rehabilitation
Neuro-oncology covers diagnostic and therapeutic management of primary and
secondary tumors of the nervous system, non-metastatic neurological
complications of cancer and genetic diseases.
Those entities, particularly heterogeneous, interface (varying degrees) with
rehabilitation (physical, cognitive or language aspects).
The majority of primary tumors are glioblastomas (WHO grade IV).
Therapeutic progress has been made in recent years. Treatment consists of
surgery, radiotherapy and chemotherapy including temozolomide. Targeted
therapies, mainly focused on angiogenesis, are just add to the usual arsenal.
Unfortunately, in most cases, the prognosis is too quickly involved and the
management of physical medicine and rehabilitation (PMR), absolutely
essential, aim to help patients to maintain their autonomy (full or partial) as long
as possible, and get at home, despite many deficits, at least with a relative
comfort.
Anaplastic gliomas (WHO grade III) represent an heterogeneous entity being
dismembered on clinical, radiological, morphological and molecular clinical
aspects. The evolution is sometimes very short in few months (rapid
transformation to a glioblastoma phenotype) or sometimes longer over 15
years (it looks like to a diffuse low-grade glioma). Rehabilitation should be
discussed on a ‘‘case by case’’ basis between neurological/oncological teams
and those from rehabilitation.
Diffuse low-grade gliomas (WHO grade II) mainly affect young people
(midlife). The most important advances in recent years concern surgery. The
slowness of the evolution allows brain plasticity. It opens the door to functional
surgery most often awake. In specialized teams, operative morbidity (excluding
expected and transient worsening observed in the weeks following the
procedure) is less than 5% (or less than 1%). Chemotherapy (usually oral and
outpatient) is available either in the case of inoperable tumors or after surgery
when growth is considered as significant (if a reoperation can not be performed).
The timing of radiotherapy is discussed. Its potential neurotoxicity and the fact
that its impact is the same regardless of the time of realization make that, in a
majority of teams, this treatment is delayed. Rehabilitation, most often
intensive, is proposed just after surgery in order to supervise and optimize
recovery. The aim is clearly to allow patients to lead a normal socio-professional
life. It is also for this entity that a randomized trial (rare in this area)
demonstrated the interest of cognitive rehabilitation. It is not impossible that, in
a near future, rehabilitation can be initiated in the preoperative period with the
aim to possibly amplify the mechanisms of plasticity and thus to promote a
surgical procedure whose quality is directly related to survival.
Other primary tumors, excluding meningiomas, are rare. Progression profiles
appear very heterogeneous across entities and each nosology (pilocytic
astrocytomas, lymphomas, medulloblastomas, germ cell tumors, nerve sheath
tumors. . .). If rehabilitation should be considered, the basis should be discussed
by all involved actors.
Cerebral and meningeal metastases are becoming increasingly important in
daily neuro-oncology. It concerns one quarter to one third of patients treated for
cancer. Although the event remains pejorative specific therapeutic are in
development: optimization of surgery, stereotactic radiotherapy, chemotherapy
or new targeted therapies and allow, for a little more than 10% of the affected
population, to obtain long survival. Again, any specific rehabilitation should be
offered at the individual level and thus discussed with all the teams.
Finally, neuro-oncology/PMR interfaces also cover the management of
neurological complications of cancer treatments, as peripheral (toxic
polyneuropathy. . .) and central (immunological or related to radiotherapy
side effects) or genetic diseases with their features (scoliosis, cerebrovascular
diseases, gliomas, cognitive deficits in neurofibromatosis, or ocular, brain or
spine hemangioblastomas for the Von Hippel Lindau disease. . .) all specific.
Transdisciplinary strategies will again, be essential.
In conclusion, the interfaces between neurooncological diseases and specialties
around the PMR are numerous. To date, only a minority of patients may benefit
from specialized care. The lack of facilities and staff could at least partially be
offset by strengthening the dialogue between specialists and the development of
joint works including collaborations such as those implemented between
SOFMER, AFSOS and ANOCEF (via the ‘‘supportive care, quality of life and
cognition’’ group). It is clearly a priority for us.
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Introduction.– Compared to manual drainage (DM), sequential pneumatic
compression is sometimes presented as less efficient. This is one of the major
consequences of the use of inadequate pumps or programs to irreversible
lymphoedema. Their substantive processing requires a retrograde program
starting at the top of the oedema.
Objective.– The response to a DM is compared to the one of a retrograde
pneumatic drainage (RPD).
Subjects and methods.– Today, the sample includes nine women (71 years old)
with an old (14 years) and persistent upper limb lymphedema. The DPR choose
was the Lymphassist1; a program of Hydroven121 (FlowtronTM, England). Its
algorithm was widely copied for the DM. The choice of the value of the
Lymphassist1 pressure is reduced to 30 or40 mmHg. The pressure of40 mmHg
was chosen for this study. The wave moves without pressure gradient. Each
treatment lasts 16 min and is followed by a rest time of 15 min. The order of
execution is drawn at random. The relative reduction of the oedema was
objectified by mercury (JSITM, SU4) gauge plethysmograph; the gauge placed
at 20 cm above the elbow, where the passage has been the most common.
Results.– DM produced a gradual reduction of oedema. It reached 11.9 ml/
100mloed after the 16 minutes of massage. After the same amount of time, the
RPD response was: 0 ml/100mloed.
Discussion.– DM assured an unsurprisingly decongestion and comparable to
our previous studies. In contrast, the Lymphassist1 showed complete
inefficiency at least into the phase of substantive treatment of a former
persistent lymphoedema of the upper limb.
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Purpose.– The world health organization advices the use of the international
classification of functioning disability and health as a basis for common
language and concepts for the health professionals. The objective of this study
was to evaluate the disability and health status after treatment for breast cancer
(i.e. body function and structure, activity, participation).
Patients and methods.– Patients receiving radiotherapy after breast cancer were
followed for one year. Functioning status were assessed before (T0), at the end
of the radiotherapy (T1), and after three (T3), six (T6) and twelve months (T12).
Body structure and function were assessed by means of: the pain threshold test,
ONCO-MPR (session AFSOS-ANOCEF-SOFMER) / Annals of Physical and Rehabilitation Medicine 56S (2013) e243–e248e246
